Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment

BACKGROUND: A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF). To find out which patients specifically benefit from pirfenidone, we analyzed in an exploratory manner the data from the phase III trial. METHODS: The patients in the phase III trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Azuma, Arata, Taguchi, Yoshio, Ogura, Takashi, Ebina, Masahito, Taniguchi, Hiroyuki, Kondoh, Yasuhiro, Suga, Moritaka, Takahashi, Hiroki, Nakata, Koichiro, Sato, Atsuhiko, Kudoh, Shoji, Nukiwa, Toshihiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216874/
https://www.ncbi.nlm.nih.gov/pubmed/22035508
http://dx.doi.org/10.1186/1465-9921-12-143

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3216874/
https://www.ncbi.nlm.nih.gov/pubmed/22035508
http://dx.doi.org/10.1186/1465-9921-12-143

Ejemplares similares